8-K: Current report filing
Published on February 9, 2000
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8 - K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): FEBRUARY 4, 2000
CYTOCLONAL PHARMACEUTICS INC.
-----------------------------
(Exact name of Registrant as Specified in Charter)
DELAWARE 0-26918 75-2402409
-------- ------- ----------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
9000 HARRY HINES BOULEVARD, SUITE 330, DALLAS, TEXAS 75235
- ---------------------------------------------------- -----
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (214) 353-2922
N/A
---
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS.
On February 4, 2000, the registrant issued the press release filed as
Exhibit 99.1 hereto and incorporated herein by reference, announcing that it
intended to call for redemption its outstanding Class C Warrants for cash
at the redemption price of $.05 per Class C Warrant. On February 7, 2000, the
registrant distributed to the registered holders of its Class C Warrants the
Notice of Redemption of Class C Warrants filed as Exhibit 99.2 hereto. Each
Class C Warrant is exercisable at an aggregate exercise price of $6.50 per Class
C Warrant prior to 5:00 p.m. (Eastern Standard Time) on March 8, 2000. If a
Class C Warrant is exercised, the holder will receive one share of common stock
(NASDAQ:CYPH) and one Class D Warrant (NASDAQ:CYPHZ) of Cytoclonal Pharmaceutics
Inc. After 5:00 p.m. on March 8, 2000, the Class C Warrants will no longer be
exercisable, and the holders will have only the right to receive the redemption
price.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit
Number Description
99.1 Press release issued February 4, 2000.
99.2 Notice of Redemption of Class C Warrants distributed
to the registered holders of Class C Warrants.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CYTOCLONAL PHARMACEUTICS INC.
Date: February 9, 2000
By:/s/ DANIEL SHUSTERMAN
----------------------------------
Daniel Shusterman
Vice President Operations
Treasurer and Chief Financial Officer
3
EXHIBIT INDEX